3rd mRNA Process Development and Manufacturing Summit

The 3rd mRNA Process Development and Manufacturing Summit returns to Boston this September, poised to help you implement high throughput process development, scale-up mRNA synthesis and purification, develop process analytics and optimize drug product formulation.

As the world's leading technical mRNA forum, 2024's brand-new agenda will see 30+ process development and manufacturing specialists from leading mRNA companies such as Moderna, Pfizer, Sanofi and BioNTech take center stage to address the industry's most prevalent bottlenecks.

Dive into two content tracks dedicated to Research Scale and IND Enabling and Clinical Scale mRNA production, as we cover the entire process from DNA synthesis and mRNA purification to drug product formulation and commercial scale manufacturing.

Join 200+ VPs, Directors and Heads of Process Development, In Vitro Transcription, CMC, MSAT and more as we seek to set manufacturing frameworks, and enable you to support your R and D and analytical teams to supercharge safe and effective mRNA drugs from research into the clinic and beyond.

URLs:
Website: https://go.evvnt.com/2431710-0?pid=10018
Tickets: https://go.evvnt.com/2431710-2?pid=10018
Brochure: https://go.evvnt.com/2431710-3?pid=10018

Prices:
Drug Developer Pricing- Conference + Workshop Day- On the Door: USD 3598.00,
Drug Developer Pricing- Conference + Focus Day- On the Door: USD 4197.00,
Drug Developer Pricing- Conference Only- On the Door: USD 2999.00,
Academic Pricing- Conference + Workshop Day- On the Door: USD 3098.00,
Academic Pricing- Conference + Focus Day- On the Door: USD 3597.00,
Academic Pricing- Conference Only- On the Door: USD 2599.00

Speakers: Sarah Muse, Senior Scientist , Sanofi, Jeffrey Ulmer, President and Chief Executive Officer , TechImmune LLC, Hang Yuan ,CTO , Innovac Therapeutics, Joseph Parrella, Vice President - Chemistry, Manufacturing and Controls , Kernal Biologics Inc., Kaixi Zhao ,Senior Scientist , Merck and Co, John Stubenrauch , Chief Operating Officer, Nutcracker Therapeutics, Azadeh Zaker ,Scientist II, Bioprocess Development , CSL Seqirus, Rajesh Krishnan ,Senior Director - Formulation, Providence Therapeutics, Soumyajit Chowdhuri , Senior Associate Engineer- Process Development and Drug Product , Sanofi, Prasun chakraborty, CEO and Founder , Genevation LTD., Jeff Kuan, Senior Manager- Drug Product Development , Gritstone Bio, Lena Wicke , Senior Director RNA Process Development, BioNTech, Travis McQuiston , Senior Director- Scientific Research , Turn Biotechnologies, Marco Marques, Lecturer- Biochemical Engineering ,University College London, Jesse Erasmus , Director- Virology , HDT Bio, Diana Posadas , Director- Strategic Research , Greenlight Biosciences, Harshal Zope , Director- MSAT , Orna Therapeutics, Florent Peral , Senior Scientist - Drug Product Development - mRNA Center of Excellence , Sanofi, Charles Cabral , Senior Director- MSAT , Arcturus Therapeutics, Yadu Balachandran, Senior Principal Engineer - mRNA Process Development ,Moderna, Gene Malin, CMC Lead , CEPI, Zoltán Kis ,Senior Lecturer (Associate Professor) , University of Sheffield, Bill Grier , Associate Director - Drug Substance Process Development ,Omega Therapeutics, Nicole Eschmann , Principal Scientist - Bioprocess, Research and Development , Pfizer, Shefal Parikh, Director- mRNA Process Development ,Chroma Medicine, John Zuris, Director , Editas Medicine, Shani Levit , Scientist II , CSL Seqirus, Krishna Sapkota, Scientist II, Beam Therapeutics, Emily Dewar, Associate Principal Scientist, Merck and Co, Alexander Lemaire , Associate Director - Process Development , Strand Therapeutics Inc., Thomas Ziegenhals , Director RNA Optimization - in vitro transcription , BioNTech, James Osborn, Sr. Scientist , Merck and Co, Craig Martin, Professor , University of Massachusetts Amherst